[go: up one dir, main page]

MX2014004813A - Regimen de dosificacion para un modulador o agonista del receptor s1p. - Google Patents

Regimen de dosificacion para un modulador o agonista del receptor s1p.

Info

Publication number
MX2014004813A
MX2014004813A MX2014004813A MX2014004813A MX2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A
Authority
MX
Mexico
Prior art keywords
dosage regimen
receptor modulator
agonist
human
patient
Prior art date
Application number
MX2014004813A
Other languages
English (en)
Inventor
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014004813A publication Critical patent/MX2014004813A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a un método de tratamiento de la esclerosis múltiple en un paciente mamífero, preferiblemente un ser humano, en necesidad de tal tratamiento, que comprende administrar al humano un modulador o agonista del receptor de S1P de acuerdo con un régimen de dosificación que se determina con referencia al conteo de linfocitos en la sangre del paciente.
MX2014004813A 2011-10-21 2012-10-18 Regimen de dosificacion para un modulador o agonista del receptor s1p. MX2014004813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549847P 2011-10-21 2011-10-21
PCT/EP2012/070692 WO2013057212A1 (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Publications (1)

Publication Number Publication Date
MX2014004813A true MX2014004813A (es) 2014-05-20

Family

ID=47022722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004813A MX2014004813A (es) 2011-10-21 2012-10-18 Regimen de dosificacion para un modulador o agonista del receptor s1p.

Country Status (18)

Country Link
US (1) US20150218090A1 (es)
EP (1) EP2768494A1 (es)
JP (1) JP2014530835A (es)
KR (1) KR20140084041A (es)
CN (1) CN103889408A (es)
AU (1) AU2012324867B2 (es)
BR (1) BR112014009141A8 (es)
CA (1) CA2852142A1 (es)
CL (1) CL2014000991A1 (es)
IL (1) IL231945A0 (es)
MX (1) MX2014004813A (es)
PH (1) PH12014500854A1 (es)
RU (1) RU2014120411A (es)
SG (2) SG11201401065RA (es)
TN (1) TN2014000132A1 (es)
TW (1) TW201320998A (es)
WO (1) WO2013057212A1 (es)
ZA (1) ZA201402283B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
EP3168237A1 (en) * 2015-11-10 2017-05-17 Dow Global Technologies LLC High pressure, free radical polymerizations to produce ethylene-based polymers
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2022037525A1 (zh) * 2020-08-20 2022-02-24 南京明德新药研发有限公司 苯乙酮肟类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1505959T1 (sl) 2002-05-16 2009-04-30 Novartis Ag Uporaba vezavnih sredstev EDG receptorjev pri raku
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN1791592B (zh) * 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CA2925175A1 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
KR20140084041A (ko) 2014-07-04
TW201320998A (zh) 2013-06-01
JP2014530835A (ja) 2014-11-20
RU2014120411A (ru) 2015-11-27
CL2014000991A1 (es) 2014-08-22
BR112014009141A8 (pt) 2017-06-20
IL231945A0 (en) 2014-05-28
TN2014000132A1 (en) 2015-07-01
BR112014009141A2 (pt) 2017-06-13
SG11201401065RA (en) 2014-09-26
ZA201402283B (en) 2015-03-25
EP2768494A1 (en) 2014-08-27
US20150218090A1 (en) 2015-08-06
CA2852142A1 (en) 2013-04-25
AU2012324867A1 (en) 2014-05-08
AU2012324867B2 (en) 2015-09-10
PH12014500854A1 (en) 2021-08-09
WO2013057212A1 (en) 2013-04-25
SG10201602279PA (en) 2016-04-28
NZ623571A (en) 2016-03-31
CN103889408A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112014010803A2 (pt) método de tratamento
MY174010A (en) Device for extracorporeal blood treatment
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
MA32981B1 (fr) Regime posologique pour un agoniste du recepteur s1p
MX2014004813A (es) Regimen de dosificacion para un modulador o agonista del receptor s1p.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MX366197B (es) Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
IN2012DN06309A (es)
BR112014009785A8 (pt) método para tratar ou reduzir efp
EA201590359A1 (ru) Лечение ревматоидного артрита
UY36099A (es) Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
FI20115306A7 (fi) Valon annostelulaite
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf